These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9079753)

  • 1. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
    Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ
    Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordant p53 and mdm-2 protein expression in vulvar squamous cell carcinoma and adjacent lichen sclerosus.
    Carlson JA; Amin S; Malfetano J; Tien AT; Selkin B; Hou J; Goncharuk V; Wilson VL; Rohwedder A; Ambros R; Ross JS
    Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):150-63. PubMed ID: 11396633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma.
    Gelb AB; Sudilovsky D; Wu CD; Weiss LM; Medeiros LJ
    Cancer; 1997 Nov; 80(9):1768-75. PubMed ID: 9351546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter.
    Hashimoto H; Sue Y; Saga Y; Tokumitsu M; Yachiku S
    Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia.
    Dellas A; Schultheiss E; Almendral AC; Gudat F; Oberholzer M; Feichter G; Moch H; Torhorst J
    Int J Cancer; 1997 Aug; 74(4):421-5. PubMed ID: 9291432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
    Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
    Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of mdm-2 and p53 protein in transitional cell carcinoma.
    Barbareschi M; Girlando S; Fellin G; Graffer U; Luciani L; Dalla Palma P
    Urol Res; 1995; 22(6):349-52. PubMed ID: 7537927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
    Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
    Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gastric cancer and tumor growth regulation. Study of cell proliferation markers and protein complex p53/p21WAF1/CIP1/mdm-2].
    Villaseca M; Araya JC; Roa I; Roa JC
    Rev Med Chil; 2000 Feb; 128(2):127-36. PubMed ID: 10962880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
    Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
    Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers.
    Haitel A; Wiener HG; Blaschitz U; Marberger M; Susani M
    Cancer; 1999 Apr; 85(7):1593-8. PubMed ID: 10193951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
    Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
    Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
    Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD
    Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study.
    Leuschner I; Langhans I; Schmitz R; Harms D; Mattke A; Treuner J;
    Pediatr Dev Pathol; 2003; 6(2):128-36. PubMed ID: 12574910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic biomarkers in renal cell carcinoma: relevance of DNA ploidy in predicting disease-related survival.
    Pinto AE; Monteiro P; Silva G; Ayres JV; Soares J
    Int J Biol Markers; 2005; 20(4):249-56. PubMed ID: 16398407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma.
    Kramer BA; Gao X; Davis M; Hall M; Holzbeierlein J; Tawfik O
    J Am Coll Surg; 2005 Oct; 201(4):565-70. PubMed ID: 16183495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
    Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma.
    Rioux-Leclercq N; Epstein JI; Bansard JY; Turlin B; Patard JJ; Manunta A; Chan T; Ramee MP; Lobel B; Moulinoux JP
    Hum Pathol; 2001 Nov; 32(11):1209-15. PubMed ID: 11727260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.